Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Female hands pointing at map | Image Credit: undrey - stock.adobe.com

January 27th 2025

Historical Redlining Increases Mortality Risk Among Young Patients With Cancer

Brooke McCormick

Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.

Edgardo S. Santos Castillero, MD, FACP, FASCO | Image credit: TOI

January 25th 2025

Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says

Edgardo S. Santos Castillero, MD, FACP, FASCO Interview by Mary Caffrey

January 22nd 2025

Flatiron Health, DeepScribe Unveil Partnership to Provide Oncology-Specific Ambient AI

Mary Caffrey

DeepScribe's technology aims to free doctors to focus on the patient visit.

January 20th 2025

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

Denise Tran, PharmD Haesuk Park, PhD Jordon Rabey, MS Seth Killion, BS S. Bobby Arelli, MD Elaine Murphy, BS Yoona Kim, PharmD, PhD

A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.

The new guideline is the NCCN’s first patient resource on the topic of cancer genetics and hereditary cancer risk. | Image credit: Connect world - stock.adobe.com

January 16th 2025

NCCN Publishes Patient Guidance on Genetic Testing for Cancer Risk

Rose McNulty

A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and testing for inherited genetic mutations linked with increased cancer risk.

Patient receiving lung cancer screening results | Image Credit: Nattakorn - stock.adobe.com

January 13th 2025

Lung Cancer Screening Facilities Least Accessible to American Indian/Alaska Native Patients, Rural Communities

Brooke McCormick

Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.

Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

Houston, TX | Image credit: Kovacs – stock.adobe.com

January 7th 2025

Decisions and Precision in Value-Based Cancer Care

Hayden E. Klein

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.

FDA approved. | Image Credit: Pawel - stock.adobe.com .jpeg

January 2nd 2025

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Pearl Steinzor

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

gastric cancer | Image credit: Crystal light - stock.adobe.com

January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

January 1st 2025

ICYMI: Highlights From ACCC Fall 2024

Pearl Steinzor

Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.

Top 5 Most-Read Oncology Articles of 2024

December 25th 2024

Top 5 Most-Read Oncology Content of 2024

Pearl Steinzor

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

December 23rd 2024

Mary Caffrey

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

chemotherapy | Image credit: Penn Medicine

December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

December 17th 2024

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

Pearl Steinzor

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

December 16th 2024

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Kristi Rosa

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

December 14th 2024

ICYMI: Highlights From COA 2024

Pearl Steinzor

The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.

December 13th 2024

Cost-Effectiveness of a Multicancer Early Detection Test in the US

Anuraag R. Kansal, PhD Ali Tafazzoli, PhD Alissa Shaul, MPH Ameya Chavan, MS Weicheng Ye, MPH Denise Zou, MA A. Mark Fendrick, MD

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program

December 12th 2024

Improving Access to Nivolumab by Lowering Age Restrictions in Clinical Trial

Pearl Steinzor

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health

December 10th 2024

How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

Pearl Steinzor

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg

December 4th 2024

Prior Authorization Delays Cause Serious Harm to Patients With Cancer

Pearl Steinzor

Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.

Highlights From ACCC Annual Meeting & Cancer Center Business Summit

December 4th 2024

ICYMI: Highlights From ACCC Spring 2024

Pearl Steinzor

Our top content from the Spring Association of Cancer Care Centers (ACCC) Annual Meeting & Cancer Center Business Summit featured topics on health care worker retention, advancements in precision medicine, and more!

November 29th 2024

From Data to Dialogue: Transforming Oncology With Real-World Evidence

Skylar Jeremias

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

FDA approval. | Image Credit: syahrir - stock.adobe.com

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

Kasey Bond, MPH, Perlmutter Cancer Center

November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

November 14th 2024

FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions

Giuliana Grossi

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.

November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH

Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.

<1 2 3 4 5 6 7 8 9 10

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions